Auxilium

Press Releases

Keyword Search
 

Below please find a listing of the most recent Auxilium press releases.

DateTitle 
Jan 27, 2015Auxilium Announces Results from Special Meeting of Stockholders
CHESTERBROOK, Pa., Jan. 27, 2015 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that it held a special meeting of its stockholders today at 8:30 a.m. ET to approve matters relating to the previously announced proposed merger with Endo International plc. The proposal to adopt the amended and restated agreement and plan of merger was passed by stockholders with approximately 84 percent of outstanding shares voting in favor. Auxil... 
Printer Friendly Version
Dec 22, 2014Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
CHESTERBROOK, Pa. and STOCKHOLM, Dec. 22, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of ... 
Printer Friendly Version
Dec 11, 2014Auxilium Announces Date for Special Meeting of Stockholders
CHESTERBROOK, Pa., Dec. 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has scheduled a special meeting of its stockholders for 8:30 a.m. ET on Tuesday, January 27, 2015 to approve matters relating to the previously announced proposed merger with Endo International plc. Auxilium stockholders of record at the close of business on December 23, 2014 will be mailed the proxy statement/prospectus in connection with the proposed merger and will be enti... 
Printer Friendly Version
Nov 20, 2014Auxilium Pharmaceuticals, Inc. Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting
Peyronie's Disease Data Presented Enable a Better Understanding of the Safety and Efficacy of XIAFLEX for Treatment of PD; First Data Presented on PD Treatment Impact on Female Partner Sexual Function CHESTERBROOK, Pa., Nov. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS (The Investigation for... 
Printer Friendly Version
Nov 20, 2014Auxilium Pharmaceuticals, Inc. Presents STENDRA Data At SMSNA Scientific Meeting
Erectile Dysfunction Data Presented in Two Moderated Posters; Findings Enable a Better Understanding of the STENDRA Clinical Profile and Provide Additional Data Regarding the Use of STENDRA as Early as Approximately 15 Minutes Before Sexual Activity CHESTERBROOK, Pa., Nov. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets fo... 
Printer Friendly Version
Nov 19, 2014Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals
DUBLIN and CHESTERBROOK, Pa., Nov. 19, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act") in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on November 18, 2014. Endo now expects the deal to close in the first quarter of 2015, subject... 
Printer Friendly Version
Nov 3, 2014Auxilium Pharmaceuticals, Inc. to Present XIAFLEX and STENDRA Data at SMSNA Scientific Meeting
Multiple Presentations Designed to Enable a Better Understanding of the Safety and Efficacy Profile of XIAFLEX for Treatment of Peyronie's Disease Additional Onset of Effect Study Results Expand Understanding of STENDRA for Treatment of Erectile Dysfunction CHESTERBROOK, Pa., Nov. 3, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CC... 
Printer Friendly Version
Oct 30, 2014Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
$109.6 Million in 3Q 2014 Net Revenues Driven by Strong XIAFLEX Growth; Company Returns to Profitability with 3Q Non-GAAP EPS of $0.27 per Share CHESTERBROOK, Pa., Oct. 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quart... 
Printer Friendly Version
Oct 20, 2014Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same ha... 
Printer Friendly Version
Oct 9, 2014Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion
- Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth - Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business - Transaction Expected to be Immediately Accretive - Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Milli... 
Printer Friendly Version
Sep 22, 2014Auxilium Provides Transaction Update
Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board") has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo") and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under... 
Printer Friendly Version
Sep 18, 2014Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting
Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution ... 
Printer Friendly Version
Sep 18, 2014VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA® (avanafil). STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a... 
Printer Friendly Version
Sep 17, 2014Auxilium Responds To Unsolicited Proposal From Endo International
Adopts One Year Stockholder Rights Plan CHESTERBROOK, Pa., Sept. 17, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today confirmed that Auxilium has received an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ENDP) to acquire all of the outstanding shares of Auxilium common stock at a price of $28.10 per share in cash and Endo stock, subject to due diligence, financing and other conditions. A copy of the uns... 
Printer Friendly Version
Sep 9, 2014Auxilium Pharmaceuticals, Inc. Announces Corporate Restructuring Designed To Streamline Operations, Maximize Cash Flow And Drive Sustainable Earnings Growth
- Expected to Reduce Annual Operating Expenses by At Least $75 Million - - Focus on Targeted R&D Spend, Consolidated Commercial Operations, Improved Manufacturing Efficiency and Streamlined G&A Expenses - CHESTERBROOK, Pa., Sept. 9, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced steps it is taking to reduce its costs and more fully support the Company's goal to drive earnings growth and build shareholder ... 
Printer Friendly Version